The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
Recent reports have put into evidence the possibility of a link between immune-related adverse events (IRAEs) and treatment outcome, patients drawing a benefit from treatment being also exposed to the risk to develop toxicity.A still unanswered question remains the biological origin(s) which can sus...
Main Authors: | Gerard Milano, Federico Innocenti, Joseph Ciccolini |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523320304447 |
Similar Items
-
Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01) -
Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews
by: WANG Xue, et al.
Published: (2020-06-01) -
Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01) -
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
by: Xiaoxiang Zhou, et al.
Published: (2020-04-01) -
IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01)